Rectify Pharmaceuticals Presents New Translational Data at EASL 2026 Supporting RTY-406, its Clinical Candidate for the Treatment of Primary Sclerosing Cholangitis

RTY-406 demonstrates significant improvements in disease relevant endpoints in a mouse model of primary sclerosing cholangitis (PSC) and proof of ...